Goingtomeet.com Press

Conference Dates: Sept 26 – 27, 2011
Venue: Radisson BLU Brussels, Belgium

PK/PD Modeling is quickly becoming a timely and cost efficient means of assessing the activity of a compound on the target.

The benefits of an effective PK/PD modeling setup include more informed decision making at earlier stages which can lead to increased understanding of a compounds safety, particularly in special populations such as pediatric/geriatric and also populations who would normally be excluded from clinical studies. Recently several new PK/PD software platforms have been released and these will also improve the ability of PK/PD scientists to bring more accurate predictions and understanding of the work they perform. This training course is aimed at more junior PK/PD scientists and also those who wish to be able to assess the new software’s ability to perform as they desire.

The course will introduce participants to the more advanced concepts, methodologies and applications of Pharmacokinetic and Pharmacodynamic modeling and simulation and quickly progress through several case studies using real, but hidden datasets which will enable them to gain a perspective of the advantages that a well-run PK/PD program can deliver to the entire development process.

Agenda request
To request the full agenda please follow the link:
http://www.nextlevelpharma.com/events/request_agenda/advanced_applications_in_pk_pd_modeling

For Booking Information contact:
Erika Vavrovicova

Tel: +421 232 660 382
Fax: +421 2 3301 0331
Email: erika@nextlevelpharma.com
Visit: www.nextlevelpharma.com

This event will provide essential perspectives from both industry, regulatory and scientific perspectives in terms of what are the factors preventing biologics from progressing further in development and the vital elements of a successful early stage strategy for biologic studies.

Attendees will achieve an advanced understanding of how to incorporate the specific biologic requirements into the strategic & operational planning for an early phase clinical trial that provides the best opportunity to save time, reduce risk, reduce costs and maximise product value.

Why attend?

* Meet experts directly involved in biologic trial design and implementation
* Learn about the specific regulatory guidance and level of proof required to satisfy the governing bodies.
* Understand the perspectives of all stakeholder involved, i.e. regulators, sponsors, CROs, SMOs, central labs and experienced biologic investigators.
* Come to benchmark, share experience and help to develop a best-practice approach to biologic clinical development.
* Build stronger relationships upon a better understanding of the challenges faced by each group, who are all vital to the planning and implementation of the study

Who will benefit

* Experienced executives from Pharma and Biotechs involved in Biologic development
* VPs, Professors, Senior Directors and Managers
* Discovery
* Pre-Clinical Development
* Exploratory development
* Early phase clinical development
* Clinical science
* Clinical Operations
* Clinical pharmacology
* PK & PD
* Drug safety & biomarkers
* Translational medicine
* Regulatory affairs

Agenda Request

To request the full agenda please follow the link:

https://www.nextlevelpharma.com/events/request_agenda/advanced_biologics_from_the_lab_to_the_clinic

Contact Details:

For Booking Information:

Tel: +421 232 662 621

Fax: +421 232 662 622

Email: erika@nextlevelpharma.com

Visit: www.nextlevelpharma.com